SG10201404913QA - Inhibitors of cognitive decline - Google Patents

Inhibitors of cognitive decline

Info

Publication number
SG10201404913QA
SG10201404913QA SG10201404913QA SG10201404913QA SG10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA
Authority
SG
Singapore
Prior art keywords
inhibitors
cognitive decline
cognitive
decline
Prior art date
Application number
SG10201404913QA
Inventor
Gilbert M Rishton
Susan Catalano
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of SG10201404913QA publication Critical patent/SG10201404913QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10201404913QA 2009-04-09 2010-04-06 Inhibitors of cognitive decline SG10201404913QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16798409P 2009-04-09 2009-04-09
US30866710P 2010-02-26 2010-02-26
US30909110P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
SG10201404913QA true SG10201404913QA (en) 2014-11-27

Family

ID=42936539

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201404913QA SG10201404913QA (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline
SG2011091352A SG176772A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011091352A SG176772A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Country Status (13)

Country Link
US (3) US8765816B2 (en)
EP (1) EP2416795B1 (en)
JP (1) JP2012523418A (en)
CN (2) CN105968022A (en)
AU (2) AU2010234518A1 (en)
BR (1) BRPI1007624A2 (en)
DK (1) DK2416795T3 (en)
ES (1) ES2545795T3 (en)
HK (1) HK1167323A1 (en)
IL (1) IL215645A0 (en)
RU (1) RU2595720C2 (en)
SG (2) SG10201404913QA (en)
WO (1) WO2010118055A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
CN102595884B (en) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 Inhibitors of cognitive decline
JP2014511373A (en) 2011-02-02 2014-05-15 コグニション セラピューティクス インク. Compounds isolated from turmeric oil and methods of use thereof
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
BR112014004414A2 (en) * 2011-08-25 2017-03-28 Cognition Therapeutics Inc compositions and methods for treating neurodegenerative disease
UA112109C2 (en) 2012-03-20 2016-07-25 Адамед Сп. З О.О. SULFONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CENTRAL NERVOUS DISEASES (CNS)
KR102266696B1 (en) * 2013-10-28 2021-06-21 드렉셀유니버시티 Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
ES2721001T3 (en) 2014-01-31 2019-07-26 Cognition Therapeutics Inc Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease
KR102614814B1 (en) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 Composition for treating neurodegenerative diseases
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois Method for treating lysosomal storage diseases with histatin peptides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321386A (en) * 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
JPS62283922A (en) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc Platelet coagulation inhibiting agent
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
JPH01180822A (en) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd Anti-delayed type allergic agent
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (en) 1990-01-11 1991-07-18 Knoll Ag Optically active 1-aryl-3-amino-butane derivs. prodn. - by fractional crystallisation of salts with optically active acid, useful as pharmaceutical intermediates
JP2818958B2 (en) * 1990-02-23 1998-10-30 塩野義製薬株式会社 4- (4-Alkoxyphenyl) -2-butylamine derivative and method for producing the same
DE4142366A1 (en) 1991-07-15 1993-06-24 Thomae Gmbh Dr K New phenylalkyl derivs. - are angiotensin II antagonists used to treat hypertension, coronary insufficiency, angina, cns disorders etc.
EP0724561B1 (en) * 1991-08-23 2004-04-14 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1093079A (en) * 1993-03-30 1994-10-05 陈英俊 The adrenaline B-blocking agent of deriving by condiment compound with methyl catechol structure and dehydro-compound thereof
ATE287390T1 (en) * 1994-10-21 2005-02-15 Nps Pharma Inc CALCIUM RECEPTOR ACTIVE COMPOUNDS
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp Diarylsultam derivatives
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
JP4312402B2 (en) 2001-07-31 2009-08-12 有限会社大長企画 Anti-depressant, anti-menopausal agent, anti-senile dementia agent, anti-Alzheimer agent
AU2002332659A1 (en) * 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
JP2004002517A (en) * 2002-05-31 2004-01-08 Dae Sil Kim Composition of soap containing ginger ingredient and method for producing the same
DE10320560A1 (en) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Prophylaxis or treatment of Alzheimer's disease and/or Parkinson's disease, by administration of ginger, specifically in food and/or as ginger extract
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2008512417A (en) 2004-09-10 2008-04-24 ユセベ ファルマ ソシエテ アノニム Sigma receptor ligand
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
DE602006012459D1 (en) 2005-03-05 2010-04-08 Abbott Gmbh & Co Kg SCREENING METHOD, METHOD FOR PURIFYING NON-DIFFINABLE A-BETA OLIGOMERS, SELECTIVE ANTIBODIES AGAINST SUCH NON-DIFFERSIBLE A-BETA OLIGOMERS, AND METHOD FOR PRODUCING THESE ANTIBODIES
US20070003641A1 (en) 2005-06-15 2007-01-04 Kim Darrick S H Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
ITRM20060007A1 (en) 2006-01-05 2007-07-06 Univ Bari SIGMA-2 RECEPTOR METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS
MX2008011754A (en) 2006-03-17 2008-09-30 Herbalscience Singapore Pte Ltd Extracts and methods comprising curcuma species.
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
JP2010527375A (en) 2007-05-15 2010-08-12 ヘリコン セラピューティクス,インコーポレイテッド Method for treating cognitive impairment by inhibition of GPR12
EP2206707B1 (en) * 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
WO2010062260A1 (en) 2008-11-29 2010-06-03 The Thailand Research Fund Virus and target cell interaction inhibition
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
CN102595884B (en) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 Inhibitors of cognitive decline
WO2011106785A2 (en) 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
BR112014004414A2 (en) 2011-08-25 2017-03-28 Cognition Therapeutics Inc compositions and methods for treating neurodegenerative disease

Also Published As

Publication number Publication date
AU2015242954B2 (en) 2016-08-25
ES2545795T3 (en) 2015-09-15
RU2011145321A (en) 2013-05-20
US8765816B2 (en) 2014-07-01
HK1167323A1 (en) 2013-01-04
RU2595720C2 (en) 2016-08-27
US9365491B2 (en) 2016-06-14
BRPI1007624A2 (en) 2016-07-26
SG176772A1 (en) 2012-01-30
US20140371324A1 (en) 2014-12-18
EP2416795A1 (en) 2012-02-15
AU2015242954A1 (en) 2015-10-29
US20160355458A1 (en) 2016-12-08
CN102458435A (en) 2012-05-16
US20120095105A1 (en) 2012-04-19
EP2416795B1 (en) 2015-06-03
DK2416795T3 (en) 2015-08-31
IL215645A0 (en) 2012-01-31
EP2416795A4 (en) 2013-12-25
WO2010118055A1 (en) 2010-10-14
CN105968022A (en) 2016-09-28
AU2010234518A1 (en) 2012-02-02
JP2012523418A (en) 2012-10-04

Similar Documents

Publication Publication Date Title
ZA201700326B (en) Inhibitors of beta-secretase
EP2391623A4 (en) Inhibitors of akt activity
EP2440054A4 (en) Pyridil-triazine inhibitors of hedgehog signaling
ZA201206424B (en) Inhibitors of semicarabazide-sensitive amine oxidase
EP2413932A4 (en) Inhibitors of akt activity
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
EP2406250A4 (en) Inhibitors of akt activity
HK1171624A1 (en) Inhibitors of cognitive decline
PL2521746T3 (en) Inhibition of amine oxidation
HK1167323A1 (en) Inhibitors of cognitive decline
ZA201206456B (en) Uses of dgati inhibitors
EP2405756A4 (en) Inhibitors of akt activity
HK1167654A1 (en) Dihydropyrrolonaphtyridinone compounds as inhibitors of jak jak dihydropyrrolonaphtyridinone
LT2506840T (en) Uses of hypoxia-inducible factor inhibitors
HK1171013A1 (en) Inhibitors of akt activity akt
PL2493496T3 (en) Use of gstp1
IL217756A0 (en) Inhibitors of jnk
GB0908609D0 (en) New use of isoQC inhibitors
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
EP2513059A4 (en) Inhibitors of akt activity
GB0903651D0 (en) Inhibitors of glyoxalase
GB0905098D0 (en) Use of biomarkers
GB0905280D0 (en) Novel uses of VEGFxxxb
IL220242A0 (en) Methods of improving cognitive functions
GB0911084D0 (en) New use of statins